Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Incidence and risk factors for hemorrhagic cystitis in unmanipulated haploidentical transplant recipients.
Ruggeri A, Roth-Guepin G, Battipaglia G, Mamez AC, Malard F, Gomez A, Brissot E, Belhocine R, Vekhoff A, Lapusan S, Isnard F, Legrand O, Gozlan J, Boutolleau D, Ledraa T, Labopin M, Rubio MT, Mohty M. Ruggeri A, et al. Among authors: lapusan s. Transpl Infect Dis. 2015 Dec;17(6):822-30. doi: 10.1111/tid.12455. Epub 2015 Nov 25. Transpl Infect Dis. 2015. PMID: 26354178
Thiotepa, Busulfan, and Fludarabine Conditioning Regimen in T Cell-Replete HLA-Haploidentical Hematopoietic Stem Cell Transplantation.
Duléry R, Bastos J, Paviglianiti A, Malard F, Brissot E, Battipaglia G, Médiavilla C, Giannotti F, Banet A, de Wyngaert ZV, Ledraa T, Belhocine R, Sestili S, Adaeva R, Lapusan S, Isnard F, Legrand O, Vekhoff A, Rubio MT, Ruggeri A, Mohty M. Duléry R, et al. Among authors: lapusan s. Biol Blood Marrow Transplant. 2019 Jul;25(7):1407-1415. doi: 10.1016/j.bbmt.2019.02.025. Epub 2019 Mar 11. Biol Blood Marrow Transplant. 2019. PMID: 30871978 Free article. Clinical Trial.
Thiotepa and antithymocyte globulin-based conditioning prior to haploidentical transplantation with posttransplant cyclophosphamide in high-risk hematological malignancies.
Peric Z, Mohty R, Bastos J, Brissot E, Battipaglia G, Belhocine R, Sestili S, Giannotti F, Vekhoff A, Ledraa T, Legrand O, Lapusan S, Isnard F, Labopin M, Bonnin A, Mediavilla C, Rubio MT, Ruggeri A, Duléry R, Malard F, Mohty M. Peric Z, et al. Among authors: lapusan s. Bone Marrow Transplant. 2020 Apr;55(4):763-772. doi: 10.1038/s41409-019-0726-7. Epub 2019 Oct 31. Bone Marrow Transplant. 2020. PMID: 31673080
Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3-mutated acute myeloid leukemia.
Battipaglia G, Ruggeri A, Massoud R, El Cheikh J, Jestin M, Antar A, Ahmed SO, Rasheed W, Shaheen M, Belhocine R, Brissot E, Dulery R, Eder S, Giannotti F, Isnard F, Lapusan S, Rubio MT, Vekhoff A, Aljurf M, Legrand O, Mohty M, Bazarbachi A. Battipaglia G, et al. Among authors: lapusan s. Cancer. 2017 Aug 1;123(15):2867-2874. doi: 10.1002/cncr.30680. Epub 2017 Apr 7. Cancer. 2017. PMID: 28387928 Free article.
Defibrotide for Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease Prophylaxis in High-Risk Adult Patients: A Single-Center Experience Study.
Picod A, Bonnin A, Battipaglia G, Giannotti F, Ruggeri A, Brissot E, Malard F, Médiavilla C, Belhocine R, Vekhoff A, Gueye MS, Lapusan S, Adaeva R, Isnard F, Legrand O, Baylatry MT, Joly AC, Labopin M, Duléry R, Mohty M. Picod A, et al. Among authors: lapusan s. Biol Blood Marrow Transplant. 2018 Jul;24(7):1471-1475. doi: 10.1016/j.bbmt.2018.02.015. Epub 2018 Mar 1. Biol Blood Marrow Transplant. 2018. PMID: 29477779 Free article.
Fractionated gemtuzumab ozogamicin in association with high dose chemotherapy: a bridge to allogeneic stem cell transplantation in refractory and relapsed acute myeloid leukemia.
Debureaux PE, Labopin M, Mamez AC, Lapusan S, Isnard F, Adaeva R, Bonnin A, Hirsch P, Delhommeau F, Battipaglia G, Duléry R, Malard F, Vekhoff A, Mohty M, Legrand O, Brissot E. Debureaux PE, et al. Among authors: lapusan s. Bone Marrow Transplant. 2020 Feb;55(2):452-460. doi: 10.1038/s41409-019-0690-2. Epub 2019 Sep 25. Bone Marrow Transplant. 2020. PMID: 31554931 Free article.
Tolerability and Efficacy of Treatment With Azacytidine as Prophylactic or Preemptive Therapy for Myeloid Neoplasms After Allogeneic Stem Cell Transplantation.
Marini C, Brissot E, Bazarbachi A, Duléry R, Sestili S, Battipaglia G, Médiavilla C, Paviglianiti A, Belhocine R, Isnard F, Lapusan S, Adaeva R, Bannet A, van de Wiegert Z, Vekhoff A, Ledraa T, Legrand O, Labopin M, Bonnin A, Ruggeri A, Malard F, Mohty M. Marini C, et al. Among authors: lapusan s. Clin Lymphoma Myeloma Leuk. 2020 Jun;20(6):377-382. doi: 10.1016/j.clml.2019.10.011. Epub 2019 Oct 23. Clin Lymphoma Myeloma Leuk. 2020. PMID: 32234295 Clinical Trial.
Thiotepa-busulfan-fludarabine as a conditioning regimen for patients with myelofibrosis undergoing allogeneic hematopoietic transplantation: a single center experience.
Memoli M, Paviglianiti A, Malard F, Battipaglia G, Brissot E, Médiavilla C, Bianchessi A, Banet A, Van de Wyngaert Z, Ledraa T, Belhocine R, Sestili S, Lapusan S, Hirsch P, Favale F, Boussaroque A, Bonnin A, Vekhoff A, Legrand O, Mohty M, Duléry R. Memoli M, et al. Among authors: lapusan s. Leuk Lymphoma. 2021 Feb;62(2):419-427. doi: 10.1080/10428194.2020.1827246. Epub 2020 Oct 5. Leuk Lymphoma. 2021. PMID: 33012207
53 results